Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 3, 2015, Pages 301-308

  Dobloug, Gerd Cecilie ^a   Garen, Torhild ^a   Brunborg, Cathrine ^a   Gran, Jan Tore ^a   Molberg, Øyvind ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cancer and mortality risk factors; Idiopathic Inflammatory Myopathy (IIM); Survival

Indexed keywords

RO ANTIBODY;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; HUMAN; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MYOSITIS; NORWEGIAN (PEOPLE); OVARY CANCER; POLYMYOSITIS; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; STANDARDIZED MORTALITY RATIO; SURVIVAL RATE; SURVIVAL TIME; FACTUAL DATABASE; INCIDENCE; MIDDLE AGED; MORTALITY; NEOPLASMS; NORWAY; RISK;

AGED; DATABASES, FACTUAL; DERMATOMYOSITIS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOSITIS; NEOPLASMS; NORWAY; POLYMYOSITIS; RISK; SURVIVAL RATE;

EID: 84955667399     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.06.005     Document Type: Article

References (48)

1. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
2. Christopher-Stine L., Plotz P.H. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol 2004, 18:331-344.
3. Airio A., Kautiainen H., Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006, 25:234-239.
4. Marie I., Hachulla E., Hatron P.Y., et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001, 28:2230-2237.
5. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 2012, 14:275-285.
6. Cox F.M., Titulaer M.J., Sont J.K., et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011, 134(Pt 11):3167-3175.
7. Cox F.M., Verschuuren J.J., Verbist B.M., et al. Detecting dysphagia in inclusion body myositis. J Neurol 2009, 256:2009-2013.
8. Benveniste O., Guiguet M., Freebody J., et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011, 134(Pt 11):3176-3184.
9. Tansley S., Gunawardena H. The evolving spectrum of polymyositis and dermatomyositis-moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 2014, 47:246-273.
10. Love L.A., Leff R.L., Fraser D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360-374.
11. Chinoy H., Fertig N., Oddis C.V., et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007, 66:1345-1349.
12. C Pikington, A Tjarnlund, M Bottai, V Werth, M.de.Visser, L Alfredsson, et al. Progress report on the Development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Pediat Rheum. 2014, 12(Suppl. 1). P94.
13. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
14. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407.
15. Targoff I.N., Miller F.W., Medsger T.A., et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997, 9:527-535.
16. Griggs R.C., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
17. Verschuuren JJ BU VEB, Badrising U.A., Van Engelen B.G., Van der Hoev, et al. Inclusion body myositis 1997, Royal Society of Medicine Press, London.
18. Rose M.R. 188th ENMC International Workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013, 23:1044-1055.
19. Rose A.L., Walton J.N. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain 1966, 89:747-768.
20. Carpenter J.R., Bunch T.W., Engel A., et al. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 1977, 4:207-214.
21. Medsger T.A., Robinson H., Masi A.T. Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum 1971, 14:249-258.
22. Maugars Y.M., Berthelot J.M., Abbas A.A., et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996, 14:263-274.
23. Hochberg M.C., Feldman D., Stevens M.B. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986, 15:168-178.
24. Sultan S.M., Ioannou Y., Moss K., et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002, 41:22-26.
25. Schiopu E., Phillips K., MacDonald P.M., et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012, 14:R22.
26. Bronner I.M., van der Meulen M.F., de Visser M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006, 65:1456-1461.
27. Danko K., Ponyi A., Constantin T., et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004, 83:35-42.
28. Yamasaki Y., Yamada H., Ohkubo M., et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 2011, 38:1636-1643.
29. Torres C., Belmonte R., Carmona L., et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006, 39:205-215.
30. Hill C.L., Zhang Y., Sigurgeirsson B., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357:96-100.
31. Barghout V.P., M.Benveniste O., et al. Assessment of mortality in sporadic inclusion body myositis; a Delphi Panel Technique (P1.025). Gen Neurol 2014, 82. [Supplement P1.025].
32. Yu K.H., Wu Y.J., Kuo C.F., et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumato 2011, 30:1595-1601.
33. Limaye V., Luke C., Tucker G., et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013, 33:965-971.
34. Madan V., Chinoy H., Griffiths C.E., et al. Defining cancer risk in dermatomyositis. part I. Clin Exp Dermatol 2009, 34:451-455.
35. Ungprasert P., Bethina N.K., Jones C.H. Malignancy and idiopathic inflammatory myopathies. North Am J Med Sci 2013, 5:569-572.
36. Buchbinder R., Forbes A., Hall S., et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001, 134:1087-1095.
37. Madan V., Chinoy H., Griffiths C.E., et al. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009, 34:561-565.
38. Sigurgeirsson B., Lindelof B., Edhag O., et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992, 326:363-367.
39. Dobloug C., Garen T., Molberg O., et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2014, http://dx.doi.org/10.1136/annrheumdis-2013-205127 [Epub ahead of print].
40. Dobloug C., Antal E., Sveberg L., et al. High prevalence of inclusion body myositis in Norway; a population based clinical epidemiology study. Eur J Neurol 2015, 22. 672-e41.
41. Marie I., Josse S., Hatron P.Y., et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res 2013, 65:800-808.
42. Mulcahy K.P., Langdon P.C., Mastaglia F. Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence. Dysphagia 2012, 27:64-69.
43. Marie I., Josse S., Decaux O., et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012, 11:739-745.
44. Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63:3439-3447.
45. Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012, 41:890-899.
46. Marie I., Josse S., Decaux O., et al. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 2013, 24:474-479.
47. Aggarwal R., Cassidy E., Fertig N., et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014, 73:227-232.
48. Madan V., Chinoy H., Griffiths C.E., Cooper R.G. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009, 34:561-565.